Forest Laboratories, Inc.  

(Public, NYSE:FRX)   Watch this stock  
Find more results for FRX
91.65
-0.48 (-0.52%)
Apr 23 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 91.23 - 92.39
52 week 35.99 - 100.88
Open 92.02
Vol / Avg. 1.40M/2.79M
Mkt cap 24.83B
P/E 157.75
Div/yield     -
EPS 0.58
Shares 270.96M
Beta 0.73
Inst. own 91%
Jul 21, 2014
Q1 2015 Forest Laboratories, Inc. Earnings Release (Estimated) Add to calendar
Apr 29, 2014
Q4 2014 Forest Laboratories, Inc. Earnings Conference Call - 10:00AM EDT - Add to calendar
Apr 29, 2014
Q4 2014 Forest Laboratories, Inc. Earnings Release - 9:30AM EDT - Add to calendar
Mar 3, 2014
Forest Laboratories, Inc. at Cowen Health Care Conference
Feb 25, 2014
Actavis plc / Forest Laboratories Inc at Citi Global Healthcare Conference - Webcast
Feb 18, 2014
Actavis plc to discuss the Acquisition of Forest Laboratories, Inc. - Webcast
Feb 12, 2014
Forest Laboratories, Inc. at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 2.04% -1.04%
Operating margin 2.46% -2.49%
EBITD margin - 4.57%
Return on average assets 0.86% -0.42%
Return on average equity 1.21% -0.56%
Employees 5,800 -
CDP Score - 56 E

Address

909 Third Avenue
NEW YORK, NY 10022
United States - Map
+1-212-4217850 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Forest Laboratories, Inc. (Forest) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company�s products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder. In February 2014, it acquired Aptalis. In February 2014, Mayne Pharma Group Ltd completed the acquisition of the ESGIC, ESGIC PLUS, LORCET and LORCET PLUS brands and related assets from Forest Laboratories, Inc.

Officers and directors

Brenton L. Saunders President, Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Francis I. Perier Jr. Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Karen Ling Chief Human Resource Officer, Senior Vice President
Bio & Compensation  - Reuters
Bill Meury Executive Vice President - Sales and Marketing
Bio & Compensation  - Reuters
Elaine Hochberg Executive Vice President - International, Strategic Planning and Government Affairs
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marco Taglietti M.D. Executive Vice President - Drug Development and Research, and Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Joe Zimmerman Senior Vice President, Chief Compliance Officer
Bio & Compensation  - Reuters
Robert Bailey Senior Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Bio & Compensation  - Reuters
Alex Kelly Senior Vice President, Chief Communications & Investor Relations Officer
Bio & Compensation  - Reuters
Kevin Walsh Senior Vice President - Operations
Bio & Compensation  - Reuters